AmerisourceBergen has struck a $6.5bn deal to acquire the majority of the Alliance Healthcare businesseses from Walgreens Boots Alliance, giving it access to Alliance’s generics assets in Europe.
US wholesaler and healthcare services provider AmerisourceBergen has struck a $6.5bn deal with Walgreens Boots Alliance to acquire the majority of the firm’s Alliance Healthcare unit, “one of the largest pharmaceutical wholesalers in Europe,” with a significant UK business. The deal value comprises $6.275bn in cash and 2 million shares of AmerisourceBergen common stock.
Highlighting as part of the deal package Alliance’s Almus range of generics – which it described as “the number one...
Melinta Therapeutics has prevailed at the Federal Circuit in a patent dispute over its reformulated intravenous antibiotic Minocin, with the appeals court upholding both infringement and validity and leaving Nexus Pharmaceuticals barred from launching a generic until 2031.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
A look at new research on the cardiovascular effects of ADHD medications and what it means for clinical care. This article explores the latest clinical and epidemiological research on the cardiovascular effects of medications commonly prescribed for ADHD, examining potential heart-related risks, underlying mechanisms, and their implications for patient safety, clinical decision-making, and long-term treatment strategies across diverse age groups and risk profiles.
